Heron Therapeutics (FRA:AXD2) Shiller PE Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
37 GF Score
Price €0.27
GF Value €1.18
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Heron Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Heron Therapeutics  (FRA:AXD2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Heron Therapeutics Shiller PE Ratio Related Terms


Heron Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics Shiller PE Ratio Chart

Heron Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Heron Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:AXD2 vs VRCA, RLYB, CSBR: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Heron Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Shiller PE Ratio falls into.


FRA:AXD2
37GF Score
Heron Therapeutics Inc FRA:AXD2
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Heron Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Heron Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.026/333.9520*333.9520
=-0.026

Current CPI (Jun. 2026) = 333.9520.

Heron Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -1.105 241.428 -1.528
201612 -1.157 241.432 -1.600
201703 -0.935 243.801 -1.281
201706 -0.712 244.955 -0.971
201709 -0.646 246.819 -0.874
201712 -0.929 246.524 -1.258
201803 -0.657 249.554 -0.879
201806 -0.462 251.989 -0.612
201809 -0.420 252.439 -0.556
201812 -0.554 251.233 -0.736
201903 -0.708 254.202 -0.930
201906 -0.558 256.143 -0.728
201909 -0.381 256.759 -0.496
201912 -0.585 256.974 -0.760
202003 -0.516 258.115 -0.668
202006 -0.542 257.797 -0.702
202009 -0.543 260.280 -0.697
202012 -0.559 260.474 -0.717
202103 -0.487 264.877 -0.614
202106 -0.515 271.696 -0.633
202109 -0.434 274.310 -0.528
202112 -0.478 278.802 -0.573
202203 -0.572 287.504 -0.664
202206 -0.520 296.311 -0.586
202209 -0.384 296.808 -0.432
202212 -0.160 296.797 -0.180
202303 -0.252 301.836 -0.279
202306 -0.323 305.109 -0.354
202309 -0.159 307.789 -0.173
202312 -0.046 306.746 -0.050
202403 -0.018 312.332 -0.019
202406 -0.056 314.175 -0.060
202409 -0.027 315.301 -0.029
202412 0.019 315.605 0.020
202503 0.009 319.799 0.009
202506 -0.017 322.561 -0.018
202509 -0.085 324.800 -0.087
202512 -0.017 324.054 -0.018
202603 -0.035 330.213 -0.035
202606 -0.026 333.952 -0.026

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.27 is trading 77.1% below its estimated GF Value™ of €1.18. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Shiller PE Ratio:
  • GF Value™: €1.18 vs. price of €0.27 (77.1% below fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
37GF Score

Get the complete analysis for FRA:AXD2

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€1.18
GF Value